Volume 63, Issue 1, Pages 158-165 (January 2013) Solifenacin Plus Tamsulosin Combination Treatment in Men With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction: A Randomized Controlled Trial  Steven A. Kaplan, Weizhong He, William D. Koltun, Jana Cummings, Tim Schneider, Allam Fakhoury  European Urology  Volume 63, Issue 1, Pages 158-165 (January 2013) DOI: 10.1016/j.eururo.2012.07.003 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Study flow diagram. BOOI=bladder outlet obstruction index; IPSS=International Prostate Symptom Score; TOCAS=tamsulosin oral controlled absorption system; SOLI=solifenacin; AE=adverse events. European Urology 2013 63, 158-165DOI: (10.1016/j.eururo.2012.07.003) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Detrusor pressure at maximum flow rate (PdetQmax): within–treatment-group mean change from baseline to week 12 and end of treatment (EOT) in the full analysis set. *p<0.005 (based on t test for change from baseline within treatment). SOLI=solifenacin; TOCAS=tamsulosin oral controlled absorption system. European Urology 2013 63, 158-165DOI: (10.1016/j.eururo.2012.07.003) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Maximum flow rate (Qmax): within–treatment-group mean change from baseline to week 12 and end of treatment (EOT) in the full analysis set. **p<0.0005 (based on t test for change from baseline within treatment). SOLI=solifenacin; TOCAS=tamsulosin oral controlled absorption system. European Urology 2013 63, 158-165DOI: (10.1016/j.eururo.2012.07.003) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 4 Postvoid residual volume (PVR): within–treatment-group mean change from baseline in the safety analysis set. *p<0.05, **p<0.005, ***p<0.0005 (based on t test for change from baseline within treatment). EOT=end of treatment; SOLI=solifenacin; TOCAS=tamsulosin oral controlled absorption system. European Urology 2013 63, 158-165DOI: (10.1016/j.eururo.2012.07.003) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 5 Average voided volume per micturition: change from baseline. *p<0.05, **p<0.005, ***p<0.0005. EOT=end of treatment; SOLI=solifenacin; TOCAS=tamsulosin oral controlled absorption system. European Urology 2013 63, 158-165DOI: (10.1016/j.eururo.2012.07.003) Copyright © 2012 European Association of Urology Terms and Conditions